This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Baxter International (BAX) Up 5.5% Since the Last Earnings Report?
by Zacks Equity Research
Baxter International (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Baxter (BAX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Baxter International Inc. (BAX), a global medical technology company, rallied to a new 52-week high of $51.43 on Mar 8, eventually closing a bit lower at $51.36.
Baxter Partners ScinoPharm, Expands in Generic Injectables
by Zacks Equity Research
Baxter International Inc. (BAX) has formed a strategic partnership with Taiwan-based process R&D and active pharmaceutical ingredient (API) manufacturer, ScinoPharm Taiwan, Ltd.
Baxter International (BAX) Q4 Earnings Beat, Revenues Lag
by Zacks Equity Research
Baxter International Inc. (BAX) reported fourth-quarter 2016 adjusted earnings of 57 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and were well above the year-ago figure of 43 cents.
Baxter International (BAX) Q4 Earnings Beat, Sales Miss
by Zacks Equity Research
Baxter International's (BAX) adjusted earnings of 57 cents per share beat the Zacks Consensus Estimate of 52 cents and increased by 14 cents from the year-ago quarter.
Will Baxter International (BAX) Disappoint in Q4 Earnings?
by Zacks Equity Research
Baxter International Inc. (BAX) is scheduled to report fourth-quarter 2016 earnings on Feb 1, before the opening bell.
Baxter (BAX): Sluggish Macro Environment Mars Prospects
by Zacks Equity Research
On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.
Is Baxter Poised to Counter Low Cyclophosphamide Sales?
by Zacks Equity Research
On Dec 30, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.
Boston Scientific Down on Risks; Innovations Raise Hope
by Zacks Equity Research
On Dec 27 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
Qiagen Poised on Fundamentals, Expansion Plans on Track
by Zacks Equity Research
On Dec 23, 2016, we issued an updated research report on Netherlands-based molecular diagnostics provider Qiagen NV (QGEN).
Myriad Genetics: United Rheumatology Selects Vectra DA Test
by Zacks Equity Research
Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience's Vectra DA assay has been added by United Rheumatology to its clinical practice guidelines for adults with rheumatoid arthritis.
Henry Schein Named 2016's Best Animal Healthcare Provider
by Zacks Equity Research
Henry Schein, Inc. (HSIC) has been recognized as the "Best Animal Healthcare Product Provider 2016".
VWR Plagued by Headwinds, Solid Fundamentals Raise Hope
by Zacks Equity Research
On Dec 20, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR).
Chemed (CHE): Roto-Rooter Solid, Reimbursement a Concern
by Zacks Equity Research
On Dec 20, we issued an updated research report on Cincinnati, OH-based Chemed Corporation (CHE).
Walgreens Boots and Rite Aid to Vend 865 Stores to Fred's
by Zacks Equity Research
Walgreens Boots Alliance Inc. (WBA) has moved forward with regards to the impending acquisition of Rite Aid by recently announcing a $950 million deal to sell 865 Rite Aid stores.
Amedisys' Unit to Buy Personal Care Provider, Home Staff
by Zacks Equity Research
Amedisys, Inc. (AMED) recently decided to buy a Massachusetts-based personal care provider, Home Staff, LLC.
CVS Health (CVS) Down on Prevailing Risks, Tepid Guidance
by Zacks Equity Research
In Dec 19, 2016, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS)
Zimmer Biomet (ZBH): Spine Group Solid, Q3 Results a Drag
by Zacks Equity Research
On Dec 19, we issued an updated research report on Warsaw, IN-based Zimmer Biomet Holdings Inc. (ZBH).
Align Technology Hits 52-Week High on Q3 & Dental Strength
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) scaled a new 52-week high of $102.1 on Dec 19, finally closing a bit lower at $100.3.
Bruker (BRKR) Buys Active Spectrum to Boost MRI Business
by Zacks Equity Research
Bruker Corporation (BRKR) recently announced the acquisition of Active Spectrum Inc., a manufacturer of innovative benchtop micro-ESR spectroscopy systems.
Hill Rom Gains on Solid Q4, Buyouts & Product Launches
by Zacks Equity Research
On Dec 16, we issued an updated research report on Batesville, IN-based medical device manufacturer, Hill-Rom Holdings, Inc. (HRC).
Hologic (HOLX) to Divest Blood Screening Business to Grifols
by Zacks Equity Research
Hologic, Inc. (HOLX) recently inked a deal to divest its stake in the blood screening business.
CVS Health Revises View for 2016 & 2017, Declares Dividend
by Zacks Equity Research
CVS Health Corporation (CVS) recently announced strategies to drive long-term growth and shareholders' value.
CVS Health Introduces Transform Diabetes Care Program
by Zacks Equity Research
CVS Health Corporation (CVS) recently unveils Transform Diabetes Care Program which will help the company's PBM clients improve health outcome of diabetic patients.
Baxter (BAX) to Acquire India-Based Claris Injectables
by Zacks Equity Research
Baxter International Inc. (BAX), a global medical technology company, has signed a definitive agreement to acquire Claris Lifesciences Limited???s subsidiary Claris Injectables Limited for almost $625 million.